Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2701 to 2715 of 9071 results

  1. Orforglipron for managing overweight and obesity in people 12 to 17 years

    Awaiting development Reference number: GID-TA12451 Expected publication date: TBC

  2. Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer

    Awaiting development Reference number: GID-TA12450 Expected publication date: TBC

  3. Niraparib for treating newly diagnosed unmethylated glioblastoma

    Awaiting development Reference number: GID-TA12449 Expected publication date: TBC

  4. Digital platforms to support rehabilitation before and after primary elective hip or knee replacement surgery

    In development Reference number: GID-HTG10887 Expected publication date:  13 October 2026

  5. Sacituzumab tirumotecan for treating endometrial cancer after platinum-based chemotherapy and immunotherapy

    Awaiting development Reference number: GID-TA12448 Expected publication date: TBC

  6. Cagrilintide–semaglutide for managing overweight and obesity

    Awaiting development Reference number: GID-TA12443 Expected publication date: TBC

  7. Ivonescimab for untreated metastatic non-small-cell lung cancer with high PD-L1 expression

    Awaiting development Reference number: GID-TA12444 Expected publication date: TBC

  8. Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis

    In development Reference number: GID-HTG10902 Expected publication date: TBC

  9. Hearing aids for adults with hearing loss

    In development Reference number: GID-HTG10886 Expected publication date:  04 February 2027

  10. Lutikizumab for treating moderate to severe hidradenitis suppurativa in people 12 years and over

    Awaiting development Reference number: GID-TA12446 Expected publication date: TBC

  11. Domestic Abuse

    In development Reference number: GID-NG10449 Expected publication date:  23 February 2027

  12. Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)

    Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making

  13. Type 2 diabetes: insulin degludec (ESNM25)

    Summary of the evidence on insulin degludec for treating type 2 diabetes to inform local NHS planning and decision-making

  14. Antimicrobial prescribing: delafloxacin for acute bacterial skin and skin structure infections (ES32)

    Summary of the evidence on antimicrobial prescribing: delafloxacin

  15. Remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn's disease and ulcerative colitis (ES35)

    Summary of the evidence on remsima (infliximab biosimilar) for subcutaneous injection for managing Crohn’s disease and ulcerative colitis